the new deal is focused on one of ImmunoGen's payload technologies, the toxic molecules that add a cell-killing punch when linked to antibodies that are used to target antigens on cancer cells.

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.